Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김용희 | - |
dc.date.accessioned | 2021-04-19T04:42:47Z | - |
dc.date.available | 2021-04-19T04:42:47Z | - |
dc.date.issued | 2020-02 | - |
dc.identifier.citation | BIOMATERIALS, v. 230, article no. 119651 | en_US |
dc.identifier.issn | 0142-9612 | - |
dc.identifier.issn | 1878-5905 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0142961219307501?via%3Dihub | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/161557 | - |
dc.description.abstract | Acute myeloid leukemia is the most frequent and life-threatening blood cancer. The main treatment is chemotherapy, sometimes followed by stem cell transplant. Resistance to chemotherapy and hepatotoxicity of the CD33-targeted therapy require an alternative therapeutic strategy. Here, we report CD64-targeted RNA interference as a novel AML therapy, which was delivered by a recombinant fusion protein of CD64-binding antibody and nona-arginine (sR9). The sR9-mediated heme oxygenase-1 siRNA (siHO-1) delivery efficiently enhanced apoptotic response to daunorubicin of AML cells and AML-targeted HO-1 silencing improved chemotherapy and prolonged survival in orthotopic myeloid leukemia model. CD64 expression was verified and HO-1-silencing-mediated chemo-sensitization was also validated in leukemic blast cells originated from AML M4/M5 patient's bone marrow. Collectively, CD64-targeted RNA interference could be a promising strategy for AML therapy and AML-targeted HO-1 suppression is expected to improve the chemotherapeutic effect in future clinical trials. | en_US |
dc.description.sponsorship | This research was partially supported by grants from the National Research Foundation of Korea (NRF-2019R1A2C3008992) and Bio & Medical technology development program (NRF-2017M3A9F5029655), the Brain Korea 21 plus program (22A20130011095), and the Korean Health Technology R&D project through the Ministry of Health and Welfare (H117C0888). | en_US |
dc.language.iso | en | en_US |
dc.publisher | ELSEVIER SCI LTD | en_US |
dc.subject | Acute myeloid leukemia | en_US |
dc.subject | Monocytic myeloid leukemia | en_US |
dc.subject | CD64-Targeted fusion protein | en_US |
dc.subject | HO-1 silencing-mediated chemo-sensitization | en_US |
dc.title | CD64-targeted HO-1 RNA interference enhances chemosensitivity in orthotopic model of acute myeloid leukemia and patient-derived bone marrow cells | en_US |
dc.type | Article | en_US |
dc.relation.volume | 230 | - |
dc.identifier.doi | 10.1016/j.biomaterials.2019.119651 | - |
dc.relation.page | 119651-119661 | - |
dc.relation.journal | BIOMATERIALS | - |
dc.contributor.googleauthor | Yong, Seok-Beom | - |
dc.contributor.googleauthor | Chung, Jee Young | - |
dc.contributor.googleauthor | Kim, Seong Su | - |
dc.contributor.googleauthor | Choi, Hyung Seok | - |
dc.contributor.googleauthor | Kim, Yong-Hee | - |
dc.relation.code | 2020048418 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF ENGINEERING[S] | - |
dc.sector.department | DEPARTMENT OF BIOENGINEERING | - |
dc.identifier.pid | yongheekim | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.